Your browser doesn't support javascript.
loading
Portalvein reconstruction with a cadaveric descending thoracic aortic homograft.
Gaffey, Ann C; Zhang, Jason; Lee, Major K; Roses, Robert; Jackson, Benjamin M; Quatromoni, Jon G.
Afiliação
  • Gaffey AC; Division of Vascular and Endovascular Surgery, Department of Surgery, University of California, San Diego, La Jolla, CA.
  • Zhang J; Division of Vascular Surgery and Endovascular Therapy, University of Pennsylvania Health System, Philadelphia, PA.
  • Lee MK; Division of Gastrointestinal Surgery, University of Pennsylvania Health System, Philadelphia, PA.
  • Roses R; Division of Endocrine and Oncologic Surgery, University of Pennsylvania Health System, Philadelphia, PA.
  • Jackson BM; Division of Endocrine and Oncologic Surgery, University of Pennsylvania Health System, Philadelphia, PA.
  • Quatromoni JG; Department of Vascular Surgery, Cleveland Clinic, Cleveland, OH.
J Vasc Surg Cases Innov Tech ; 8(2): 294-297, 2022 Jun.
Article em En | MEDLINE | ID: mdl-35647419
ABSTRACT
Improvements in chemoradiotherapy have rendered complex pancreatic cancers involving the portal vein (PV) amenable to resection. PV reconstruction (PVR) is an essential component. Various conduits have been proposed; however, the optimal choice remains unknown. Fourteen patients underwent PVR with a cadaveric descending thoracic aortic homograft from 2014 to 2020. The primary diagnosis was pancreatic cancer. The splenic vein was ligated in seven patients (50%). The 30-day and 3-, 12-, and 24-month primary patency rates were 100%, 86%, 76%, and 76%, respectively. We found a cadaveric descending thoracic aortic homograft is an excellent conduit for PVR, given the optimal size, rapidly availability, favorable risk profile, and absence of harvest site complications.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article